ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AbbVie Drops Plan To Purchase Shire

by Michael McCoy
October 20, 2014 | APPEARED IN VOLUME 92, ISSUE 42

The U.S. drug company AbbVie is scuttling its $54 billion acquisition of the British drugmaker Shire in light of new U.S. tax regulations. When announced in July, the deal would have allowed AbbVie to reincorporate in the U.K. and considerably lower its tax rate. However, last month, the U.S. Treasury Department announced new rules that would make such transactions, known as inversions, less lucrative. AbbVie’s board will now recommend that its shareholders vote against the purchase. Shire says it is considering the situation. It recently reminded AbbVie that AbbVie must pay a $1.6 billion breakup fee if it cancels the deal.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment